// App-Quantinova.ai

3259 : ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing

Researchers

Presenter

  • C Pham

Principal Investigators

  • T Spindler

  • E Hwang

  • A Brito

  • Y Bulliard

  • Blake T Aftab

Medical Centers

  • Atara Biotherapeutics, Thousand Oaks, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved